Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00742183 · ClinicalTrials.gov registry record · NA
Evaluating the Cost-effectiveness, Efficacy, Safety and Tolerance of Mepilex® Ag Versus Silvadene®
A NA study of Second Degree Burn, sponsored by Molnlycke Health Care AB.
- Completed
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 10
- Study locations
NCT00742183: Completed NA study of Second Degree Burn, sponsored by Molnlycke Health Care AB.
NCT00742183 is a NA study of Second Degree Burn that has completed, run by Molnlycke Health Care AB. The registered enrollment target is 100 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). The trial reports 10 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00742183, a NA study of Second Degree Burn, has completed, sponsored by Molnlycke Health Care AB.
- COMPLETED
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 10
- Study locations
Study Summary
The primary objective is to compare the incremental costs (direct and indirect) and benefits (healing outcomes, quality of life) of using foam silver dressing (Mepilex® Ag) to a Silver sulfadiazine 1% cream (Silvadene®) from the perspective of the health care provider. The secondary objectives are to investigate the safety, the tolerance and the performance on burn status including pain.
Primary Outcome
The incremental cost-effectiveness ratio is calculated as the difference in total costs in each group divided by the difference in rate of full re-epithelialization (taken from the survival curve) at 20 days in each group (Δcosts/ Δeffects). Total costs were calculated based on the costs of primary and secondary dressings, silver sulphadiazine cream and estimated application, labor, supplies and pain medications. These costs were estimated from a representative sample of each population, across
Conditions Studied
Interventions
- DEVICE Mepilex
- DEVICE Silvadene
Study Locations (10)
California
- LA County Hospital & USC Medical Center - Los Angeles
District of Columbia
- The Burn Center, Washington Hospital Center - Washington D.C.
Florida
- Shands Burn Center, University of Florida - Gainesville
Georgia
- Joseph Still Burn Center - Augusta
Iowa
- UI Burn Treatment center - Iowa City
New York
- Cornell Medical Center - New York
Oklahoma
- Paul Silverstein Burn center - Oklahoma City
Pennsylvania
- St Christopher's Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-11 |
| Phase | NA |
What the finished NCT00742183 record still lists
NCT00742183 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Second Degree Burn appearing as the primary indexed condition, and to 2 interventions - of which Mepilex is the first listed.
NCT00742183 lists 10 locations in 10 states (California, District of Columbia, Florida).
Frequently Asked Questions
What is clinical trial NCT00742183 about?
NCT00742183 is a clinical study titled "Evaluating the Cost-effectiveness, Efficacy, Safety and Tolerance of Mepilex® Ag Versus Silvadene®". The primary objective is to compare the incremental costs (direct and indirect) and benefits (healing outcomes, quality of life) of using foam silver dressing (Mepilex® Ag) to a Silver sulfadiazine 1% cream (Silvadene®) from the perspective of the health care provider. The secondary objectives are ...
What is the current status of trial NCT00742183?
This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2008-08. Estimated completion is 2009-11.
What conditions does trial NCT00742183 study?
This clinical trial studies the following conditions: Second Degree Burn.
What interventions are being tested in trial NCT00742183?
The interventions under investigation include: Mepilex (DEVICE), Silvadene (DEVICE).
Who is sponsoring clinical trial NCT00742183?
This trial is sponsored by Molnlycke Health Care AB, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00742183 being conducted?
This trial has 10 study locations across California, District of Columbia, Florida, Georgia, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Second Degree Burn
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00742183's enrollment target sits among peer trials
100 840th of 2000 higher than 1,081 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia